DHE is an established and highly-effective option for acute migraine treatment. INP104 is an investigational new drug-device combination product being studied for acute migraine headache. It is comprised of an intranasal formulation of DHE and Impel's POD device.
The POD is a simple-to-use device designed to deliver consistent and predictable doses of drug. INP104 delivers DHE to the richly vascularized upper nasal cavity, offering rapid bioavailability without injection.
Impel NeuroPharma, a privately held company devoted to creating therapies for central nervous system diseases, has multiple therapies in clinical development to treat conditions such as migraine, Parkinson's, and Alzheimer's.
The company's products are based on a novel nasal drug delivery platform called POD technology which administers liquid or dry medication to the deep nasal cavity, enabling entirely new categories of drugs, including biologics, to be administered using a cost-effective, disposable, non-invasive method.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference